Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: High cure rates but increased risk of aseptic osteonecrosis

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1254-1259

  Fossa A ^a   Fiskvik, I H ^a   Kolstad, A ^a   Lauritzsen, G F ^a   Aurlien, E ^a   Blystad, A K ^a   Hole, K H ^a   Ikonomou, I M ^a   Holte, H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Hodgkin lymphoma; Osteonecrosis; Steroids

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ARTICLE; ASEPTIC NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CATHETER THROMBOSIS; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART DISEASE; HIGH RISK PATIENT; HIP ARTHROPLASTY; HUMAN; KIDNEY VEIN THROMBOSIS; LEUKOPENIA; LUNG DISEASE; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEONECROSIS; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; PROCARBAZINE; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; VINCRISTINE; YOUNG ADULT;

EID: 84860485218     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr385     Document Type: Article

References (20)

1. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23: 6400-6408.
2. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 497-506.
3. Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)? Cancer Invest 2006; 24: 713-717.
4. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
5. Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-4554.
6. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-811.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
8. Bauer K, Herbst C, Brillant C et al. Eleventh biannual report of the Cochrane Haematological Malignancies Group: focus on Hodgkin lymphoma. J Natl Cancer Inst 2010; 102: E1.
9. Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
10. Engel C, Loeffler M, Schmitz S et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000; 11: 1105-1114.
11. Eichenauer DA, Haverkamp H, Behringer K et al. Secondary MDS/AML in Hodgkin's lymphoma patients treated within German Hodgkin Study Group (GHSG) clinical trials after introduction of the BEACOPP protocol. Blood 2010; 116: (Abstr 2682) (ASH Annual Meeting Abstracts).
12. Sieniawski M, Reineke T, Josting A et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008; 19: 1795-1801.
13. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-7564.
14. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
15. Niitsu N, Okamoto M, Tomita N et al. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1908-1914.
16. Sieber M, Bredenfeld H, Josting A et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 1734-1739.
17. Diehl V, Haverkamp H, Mueller R et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma(HL): final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2009; 27: (Abstr 8544).
18. Powell C, Chang C, Naguwa SM et al. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev 2010; 9: 721-743.
19. Thornton MJ, O'Sullivan G, Williams MP et al. Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Clin Radiol 1997; 52: 607-612.
20. Ellis J, MacLeod U, Sammon D et al. Osteonecrosis following treatment for Hodgkin's disease. Clin Lab Haematol 1994; 16: 3-8.